Skip to main content
Premium Trial:

Request an Annual Quote

Ortho-McNeil Pharma Licenses Additional Component of Cellzome s Alzheimer Program

NEW YORK, May 23 (GenomeWeb News) - Ortho-McNeil Pharmaceutical has licensed another part of Cellzome's proteomics-based Alzheimer's disease program, exercising an option under the terms of a collaboration signed between the two companies in March, Cellzome said today.

 

Cellzome will receive an additional access fee for its proteomics technology and continued research funding. Johnson & Johnson Pharmaceutical Research and Development, an affiliate of Ortho-McNeil, will continue to provide research support.

 

The gamma secretase modulator program licensed by Ortho-McNeil includes small molecules for development as oral drugs for the treatment of Alzheimer's disease.